Beyfortus approved in China for the prevention of RSV disease in infants
On Jan. 4, 2024, AstraZeneca Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, was approved in China for the…
Year: 2024
On Jan. 4, 2024, AstraZeneca Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, was approved in China for the…